Efficacy, Safety Evaluation and Biomarker Screening of GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The clinical trial is designed to evaluate the safety and efficacy of GEMOX combined with targeted therapy and immunotherapy for patients with advanced cholangiocarcinoma, and screen the potential biomarkers
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• Male or female, 18 years old ≤ age ≤ 70 years old
• ECOG PS scores 0-1
• Expected survival time \> 12 weeks
• Advanced cholangiocarcinoma confirmed by histopathology and/or cytology, locally advanced (inoperable) or distant metastasis, and with at least one measurable lesion that has not been locally treated (per RECIST 1.1 criteria)
• Not received any previous systemic or local treatment for the tumor
• Sufficient organ and bone marrow function
Locations
Other Locations
China
Tianjin Medical University Cancer Institute & Hospital
RECRUITING
Tianjin
Contact Information
Primary
Wei Liu, MD
mail4luwei@163.com
+86 22-27468682
Backup
Ningning Zhang, MD
mail4ningning@163.com
15822153931
Time Frame
Start Date: 2022-01-15
Estimated Completion Date: 2026-01-15
Participants
Target number of participants: 146
Treatments
Experimental: group 1
GEMOX+Lenvatinib+Toripalimab
Experimental: group 2
GEMOX+Toripalimab
Related Therapeutic Areas
Sponsors
Leads: Tianjin Medical University Cancer Institute and Hospital